Kalaris Therapeutics (KLRS)
Develops TH103 for neovascular and exudative retinal diseases.
Something off on this page? Send us feedback.
Develops TH103, an investigational anti-VEGF fusion protein for neovascular retinal diseases. Its current model centers on clinical development of this single disclosed candidate after the merger that created the KLRS-listed issuer.
Develops TH103, an investigational anti-VEGF fusion protein for neovascular retinal diseases. The clinical-stage program is being evaluated for neovascular age-related macular degeneration, with planned development in diabetic macular edema and retinal vein occlusion.
The current operating business came from the 2025 merger of AlloVir and Legacy Kalaris, after which the Nasdaq-listed issuer adopted the Kalaris name and KLRS ticker. Its development model centers on repeat-dose clinical evaluation of TH103 for safety, efficacy, and regimen selection in the ongoing program. The business therefore depends on clinical execution around its single disclosed product candidate.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $93.5M · Total debt $1.4M · Total assets $99.5M · Shareholders' equity $57.7M
- Revenue
- $0
- Operating income
- −$12.4M
- Net income
- −$11.5M
No dividends on record.
| Institutions58 holders · as of Mar 31, 2026 | 78.05% | 18.58M shares | |
| Insiders4 holders · as of Jul 27, 2026 | 3.62% | 861.8K shares | |
| Strategic holders1 holder · as of Mar 25, 2025 | 48.09% | 11.45M shares | |
| Adds to | 129.76% |
23.80M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (23.80M in the company's Sep 3, 2026 report, 21.83M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 129.76%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Samsara Biocapital, LLCInstitution | 54.39% | 12.95M | 13Fas of Mar 31, 2026 |
Samsara BioCapital GP, LLCStrategic10 percent owner | 48.09% | 11.45M | Form 4filed Mar 25, 2025 ↗ |
RTW Investments, LPInstitution | 5.46% | 1.30M | 13Fas of Mar 31, 2026 |
Paradigm Biocapital Advisors LPInstitution | 2.94% | 700,000 | 13Fas of Mar 31, 2026 |
Alyeska Investment Group, L.P.Institution | 2.41% | 572,687 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 20, 2026 | Srinivas Akkaraju | director, 10 percent owner: | +244,300 | $4.83 |
| Mar 20, 2026 | Brett R. Hagen | officer: Chief Accounting Officer | −1,915 | $6.72 |
| Dec 18, 2025 | Srinivas Akkaraju | director, 10 percent owner: | +479,847 | $10.42 |
- Regeneron
Marketed anti-VEGF franchise across nAMD, DME, and RVO.
- Kodiak Sciences
Late-stage retinal programs include KSI-501 for wet AMD.
- EyePoint
Phase 3 sustained-delivery retinal treatment for wet AMD and DME.
- Novartis (ADR)
Marketed Beovu anti-VEGF treatment for wet AMD.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kalaris Therapeutics | $3.76 | −3.60% | $85.1M | — | — | — | — |
| Regeneron | $850.48 | −0.18% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Kodiak Sciences | $37.40 | −0.29% | $2.35B | — | — | — | — |
| EyePoint | $4.78 | −0.21% | $401.6M | — | — | 144.0 | −90.5% |
| Novartis (ADR) | $161.74 | −0.43% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 22.8 | 15.7 | 5.7 | +0.9% |